Skip to content

Trizivir non-inferior to unboosted atazanavir in treatment-naive

Treatment of acute hepatitis C produces good response rates in HIV-positive patients

HIV/HCV co-infected patients respond to re-treatment with pegylated interferon plus ribavirin

16% of drug-naive entering GSK US studies already have resistance

Nevirapine hepatotoxicity after treatment switch no more likely at higher CD4 counts

Suspected abacavir hypersensitivity less likely to be diagnosed in people of African ethnicity

HIV prevalence among young women in Botswana falls to lowest level since early 1990s, but still high

No lipid increase with Merck integrase inhibitor at 24 weeks

No fat loss with tenofovir after five years